investigated the efficacy of Datopotomab deruxtecan at 6 mg/kg Q3w in patients with advanced or metastatic NSCLC with actionable genomic alterations (EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping, or RET) who have already received at least one line of target therapy and CT. This evidence concerns the gene EGFR and non-small cell lung carcinoma.